002551 Shenzhen Glory Medical
- 2.51
- +0.13+5.46%
Shenzhen Glory Medical News
Shenzhen Glory Medical (002551.SZ): Repurchase completed, a total of 2,999.47 million yuan was spent to repurchase 1,030,300 shares.
Shenzhen Glory Medical (002551.SZ) announced on June 7 that, as of the disclosure date of this announcement, the deadline for the company's share buyback has expired. As of the disclosure date of this announcement, the company has repurchased a total of 1.0303 million shares of the company through the repurchase special securities account by centralized bidding method, accounting for 0.12% of the total share capital of the company, with the highest fill price of 3.10 yuan/share and the lowest fill price of 2.57 yuan/share, and the total amount paid was 2.99947 million yuan (excluding trading fees).
Shenzhen Glory MedicalLtd (SZSE:002551 Investor Three-year Losses Grow to 58% as the Stock Sheds CN¥431m This Past Week
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long term Shenzhen Glory Medical Co.,Ltd. (SZSE:002551) shareholders know that all t
Shangrong Medical (002551.SZ): Initial repurchase of 400,000 shares
Gelonghui, May 10, 丨 Shangrong Medical (002551.SZ) announced that on May 10, 2024, for the first time, the company repurchased 400,000 shares of the company's shares through a special stock repurchase securities account, accounting for 0.05% of the company's current total share capital (based on the company's total share capital as of May 9, 2024). The maximum transaction price was 3.10 yuan/share, and the minimum transaction price was 3.08 yuan/share. The total transaction amount was 1,236,000.00 yuan (excluding transaction fees).
Shangrong Medical (002551.SZ) reported first-quarter results, net profit of 13.8835 million yuan, an increase of 97.44% over the previous year
According to Zhitong Finance App, Shang Rong Healthcare (002551.SZ) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 276 million yuan, a year-on-year decrease of 10.75%; net profit attributable to shareholders of listed companies was 13.8835 million yuan, an increase of 97.44% year on year; net profit attributable to shareholders of listed companies deducted 63.35 million yuan per share without recurring profit and loss, an increase of 3.80%; basic earnings per share were 0.02 yuan/share.
Shangrong Medical (002551.SZ) reported 2023 results, with a net loss of 149 million yuan, a year-on-year decrease of 51.67%
Shangrong Medical (002551.SZ) released its 2023 annual report, with revenue of 1,193 billion yuan, compared with...
Optimistic Investors Push Shenzhen Glory Medical Co.,Ltd. (SZSE:002551) Shares Up 28% But Growth Is Lacking
Those holding Shenzhen Glory Medical Co.,Ltd. (SZSE:002551) shares would be relieved that the share price has rebounded 28% in the last thirty days, but it needs to keep going to repair the recent dam
Shangrong Medical (002551.SZ) plans to buy back A shares no more than 8.58 million yuan
Gelonghui, March 10 | Shangrong Medical (002551.SZ) announced that in view of recent large fluctuations in the company's stock price, based on confidence in the company's future sustainable development and reasonable judgment on the company's long-term value, in order to effectively protect the interests of shareholders, enhance investor confidence, and comprehensively consider business development prospects, the company plans to raise its own funds to buy back some of the company's A-shares through centralized bidding to protect the company's value and shareholders' rights. The total capital of this repurchase is not more than RMB 8.58 million, and the price of the shares repurchased is no more than RMB 4.29 per share.
Risks Still Elevated At These Prices As Shenzhen Glory Medical Co.,Ltd. (SZSE:002551) Shares Dive 29%
The Shenzhen Glory Medical Co.,Ltd. (SZSE:002551) share price has fared very poorly over the last month, falling by a substantial 29%. The drop over the last 30 days has capped off a tough year for
Shenzhen Glory Medical Co.,Ltd.'s (SZSE:002551) Market Cap Dropped CN¥507m Last Week; Individual Investors Bore the Brunt
Key Insights Significant control over Shenzhen Glory MedicalLtd by individual investors implies that the general public has more power to influence management and governance-related decisions A tota
Shang Rong Medical (002551.SZ): Pre-loss of 100 million yuan to 150 million yuan in 2023
Gelonghui, January 26 | Shangrong Medical (002551.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 10 million yuan to 150 million yuan, an increase of 67.54% — 51.31% over the same period last year; net profit loss after deducting non-recurring profit and loss was 105.1749 million yuan to 155.1749 million yuan, an increase of 67.63% — 52.25% over the same period last year; basic earnings loss per share was 0.118 yuan/share — 0.178 yuan/share. During the reporting period, the company's holding subsidiary Hefei Pulder Medical Products Co., Ltd.
Shangrong Medical (002551.SZ) and related parties accepted the Shenzhen Regulatory Bureau's decision on administrative supervision measures
Shang Rong Medical (002551.SZ) issued an announcement. The company and related parties will accept it on November 27, 2023...
Shang Rong Healthcare (002551.SZ): No downward revision of the “Shang Rong to Debt” conversion price
Glonghui on October 31 | Shang Rong Medical (002551.SZ) announced that as of October 31, 2023, the closing price of Shenzhen Shangrong Medical Co., Ltd. stock has been lower than 90% of the current stock conversion price for at least 15 out of 30 consecutive trading days, which has triggered a downward revision clause on the “Shang Rong to Bonds” conversion price. After the 15th interim meeting of the 7th board of directors of the company deliberated and passed the “Proposal on not revising the conversion price of Shang Rong to Bonds” downward, the board of directors of the company decided not to exercise a downward revision of the stock conversion price at this time. Furthermore, within the next six months (i.e. 2023
Shangrong Medical (002551.SZ) released the first three quarter results, net profit of 135.151,000 yuan, an increase of 130.11%
Shangrong Medical (002551.SZ) released its report for the third quarter of 2023. The company's revenue for the first three quarters was 9...
Shang Rong Medical (002551.SZ): Net profit of 1.5531 million yuan in the first half of the year reversed losses year-on-year
Glonghui, August 28丨Shang Rong Medical (002551.SZ) announced its 2023 semi-annual report. Operating income for the reporting period was 600 million yuan, down 4.40% from the previous year; net profit attributable to shareholders of listed companies was 1,15531 million yuan, turning a loss into a profit; net profit attributable to shareholders of listed companies was 6.6574 million yuan after deducting non-recurring profit and loss; basic earnings per share of 0.01 yuan.
Shang Rong Healthcare (002551.SZ): Preliminary profit of 8 million yuan to 10 million yuan in the first half of the year reversed the year-on-year loss
On July 13丨Shang Rong Medical (002551.SZ) announced the 2023 semi-annual results forecast. Net profit for the reporting period attributable to shareholders of listed companies was 8 million yuan to 10 million yuan, turning a loss into a profit from the previous year; net profit profit after deducting non-recurring profit and loss was 3.4787 million yuan to 5.4787 million yuan; basic earnings per share of 0.009 yuan/share - 0.012 yuan/share. Reasons for changes in performance: 1. In the reporting period, due to exchange rate fluctuations, which affected the company's exchange losses, decreased significantly year on year; 2. Due to the year-on-year decrease in loan amounts, it affected the company's interest expenses on the same period
Shenzhen Glory Medical Dismisses Claims of Staff Layoffs
Shenzhen Glory Medical (SHE:002551) refuted media reports regarding alleged staff layoffs and insufficient orders by the company. The Chinese medical device company said it has noted media reports fro
Shang Rong Medical (002551.SZ) clarifies that the number of employees in the Shenzhen Production Division is about 43. The relevant adjustments will not affect the company's daily operations
According to the Zhitong Finance App, Shang Rong Medical (002551.SZ) issued an announcement. The company recently paid attention to Times Finance and other media reports such as “The company is suspected to have insufficient orders, employees are on 'summer vacation', and there are only single digits left for employees working in the production division.” In order to avoid media reports from misleading investors, clarifications are now being made. After verification, it is true that some employees of the company's Shenzhen production division are on vacation due to the company's production capacity adjustments, but it is untrue that there are only single digits left on the job. The company explains the above media reports as follows: The company's Shenzhen production division provides the production of supporting products for the company's medical engineering business
Shenzhen Glory Medical Sees Loss of Up to 480 Million Yuan for 2022
12:19 AM EST, 01/24/2023 (MT Newswires) -- Shenzhen Glory Medical (SHE:002551) expects to book a loss of between 380 million yuan and 480 million yuan for 2022, turning around from the profit of 59.3
Health Check: How Prudently Does Shenzhen Glory MedicalLtd (SZSE:002551) Use Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart m
Shenzhen Glory Medical Co.,Ltd.'s (SZSE:002551) Market Cap Rose CN¥524m Last Week; Individual Investors Who Hold 59% Profited and so Did Insiders
A look at the shareholders of Shenzhen Glory Medical Co.,Ltd. (SZSE:002551) can tell us which group is most powerful. We can see that individual investors own the lion's share in the company with 59%
Analysis
Price Target
No Data
